Valuation: Rezolute, Inc.

Market Cap 527M 462M 426M 398M 747M 49.67B 763M 5.11B 1.98B 24.55B 1.98B 1.93B 85.12B P/E 2026 *
-7.2x
P/E 2027 * -7.75x
Enterprise Value 527M 462M 426M 398M 747M 49.67B 763M 5.11B 1.98B 24.55B 1.98B 1.93B 85.12B EV / Sales 2026 *
-
EV / Sales 2027 * 229x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day+0.20%
1 week+0.40%
Current month+52.73%
1 month+51.81%
3 months+68.56%
6 months+88.76%
Current year+113.56%
1 week 4.86
Extreme 4.86
5.26
1 month 3.19
Extreme 3.19
5.26
Current year 1.87
Extreme 1.87
5.26
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
15.26
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Date Insider Type Main position Quantity % Market Cap.
03-29Buy

Chief Financial Officer

10,000 0.0115%
03-01Tax

Chief Executive Officer

27,618 0.0317%
03-01Tax

Chief Financial Officer

11,438 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%+0.40%+15.86%+143.48% 527M
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average +0.12%+4.34%+39.73%+132.02% 22.68B
Weighted average by Cap. +0.26%+5.12%+48.42%+122.73%

Financials

2026 *2027 *
Net sales - 2.3M 2.02M 1.86M 1.74M 3.27M 217M 3.34M 22.38M 8.66M 107M 8.65M 8.46M 372M
Net income -72.7M -63.74M -58.76M -55.01M -103M -6.86B -105M -706M -273M -3.39B -273M -267M -11.75B -75.12M -65.86M -60.71M -56.84M -107M -7.09B -109M -730M -282M -3.5B -282M -276M -12.14B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
26-06-26 US$5.040 +0.20% 6,577,310
26-06-25 US$5.030 0.00% 1,262,200
26-06-24 US$5.030 +2.86% 2,689,920
26-06-23 US$4.890 -5.05% 1,652,565
26-06-22 US$5.150 +2.59% 3,111,906
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.040USD
Average target price
7.667USD
Spread / Average Target
+52.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock